Guijarro Castro, Cristina
Spasticity improvement in patients with relapsing–remitting multiple sclerosis switching from interferon-β to glatiramer acetate: The Escala Study. [artículo] - Journal of the Neurological Sciences, 2012 - 315(1-2):123-8.
Formato Vancouver:
Meca-Lallana JE, Balseiro JJ, Lacruz F, Guijarro C, Sánchez O, Cano A, et al. Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. J Neurol Sci. 2012 Apr 15;315(1-2):123-8.
PMID: 22133480
Contiene 20 referencias
Background: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment
in multiple sclerosis (MS) patients who previously received interferon-β (IFN-β).
Objective: To evaluate changes in spasticity in MS patients switching from IFN-β to GA.
Methods: Observational, multicentre study in patients with relapsing–remitting MS (RRMS) and spasticity
switching from IFN-β to GA. The primary endpoint comprised changes on Penn Spasm Frequency Scale
(PSFS), Modified Ashworth Scale (MAS), Adductor Tone Rating Scale (ATRS), and Global Pain Score (GPS)
at months 3 and 6 after starting GA.
Results: Sixty-eight evaluable patientswere included (mean age,41.7±9.5 years; female,70.6%; mean time from
MS diagnosis to starting GA,7.6±5.7 years). Previous treatments were subcutaneous IFN-β1a in 42.6% patients,
intramuscular IFN-β1a in 41.2% and IFN-β1b in 32.4%,whosemean durations were 3.5±3.3, 2.7±2.5 and 4.4±
3.6 years, respectively. Statistically significant reductions in mean scores on all spasticity measurements
were observed from baseline to month 3 (PSFS, 1.7±0.9 vs 1.4±0.6, pb0.01; MAS, 0.7±0.5 vs 0.6±0.5,
pb0.01; highest MAS score, 1.9±0.8 vs 1.7±0.8, pb0.01; ATRS, 1.6±0.6 vs 1.4±0.6, pb0.01; GPS, 29.4± 22.1 vs 24.7±19.4, pb0.01) and from baseline to month 6 (PSFS, 1.7±0.9 vs 1.3±0.6, pb0.01; MAS, 0.7±0.5 vs 0.5±0.5, pb0.01; highest MAS score, 1.9±0.8 vs 1.5±0.9, pb0.01; ATRS, 1.6±0.6 vs 1.3±0.6, pb0.01; GPS, 29.4±22.1 vs 19.1±14.8, pb0.01).
Conclusion: Spasticity improvement in terms of spasm frequency,muscle tone and pain can be noted after three
months and prolonged for six months of GA treatment.
Spasticity improvement in patients with relapsing–remitting multiple sclerosis switching from interferon-β to glatiramer acetate: The Escala Study. [artículo] - Journal of the Neurological Sciences, 2012 - 315(1-2):123-8.
Formato Vancouver:
Meca-Lallana JE, Balseiro JJ, Lacruz F, Guijarro C, Sánchez O, Cano A, et al. Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. J Neurol Sci. 2012 Apr 15;315(1-2):123-8.
PMID: 22133480
Contiene 20 referencias
Background: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment
in multiple sclerosis (MS) patients who previously received interferon-β (IFN-β).
Objective: To evaluate changes in spasticity in MS patients switching from IFN-β to GA.
Methods: Observational, multicentre study in patients with relapsing–remitting MS (RRMS) and spasticity
switching from IFN-β to GA. The primary endpoint comprised changes on Penn Spasm Frequency Scale
(PSFS), Modified Ashworth Scale (MAS), Adductor Tone Rating Scale (ATRS), and Global Pain Score (GPS)
at months 3 and 6 after starting GA.
Results: Sixty-eight evaluable patientswere included (mean age,41.7±9.5 years; female,70.6%; mean time from
MS diagnosis to starting GA,7.6±5.7 years). Previous treatments were subcutaneous IFN-β1a in 42.6% patients,
intramuscular IFN-β1a in 41.2% and IFN-β1b in 32.4%,whosemean durations were 3.5±3.3, 2.7±2.5 and 4.4±
3.6 years, respectively. Statistically significant reductions in mean scores on all spasticity measurements
were observed from baseline to month 3 (PSFS, 1.7±0.9 vs 1.4±0.6, pb0.01; MAS, 0.7±0.5 vs 0.6±0.5,
pb0.01; highest MAS score, 1.9±0.8 vs 1.7±0.8, pb0.01; ATRS, 1.6±0.6 vs 1.4±0.6, pb0.01; GPS, 29.4± 22.1 vs 24.7±19.4, pb0.01) and from baseline to month 6 (PSFS, 1.7±0.9 vs 1.3±0.6, pb0.01; MAS, 0.7±0.5 vs 0.5±0.5, pb0.01; highest MAS score, 1.9±0.8 vs 1.5±0.9, pb0.01; ATRS, 1.6±0.6 vs 1.3±0.6, pb0.01; GPS, 29.4±22.1 vs 19.1±14.8, pb0.01).
Conclusion: Spasticity improvement in terms of spasm frequency,muscle tone and pain can be noted after three
months and prolonged for six months of GA treatment.
